| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/04/2006 | US20060094648 Methods for treating or preventing ischemic injury |
| 05/04/2006 | US20060094647 Treatment of inflammatory bowel disease using growth factors |
| 05/04/2006 | US20060094646 Methods for inhibiting growth of prolactin-responsive cancer cells with cyclosporine A or other cyclophilin inhibitors |
| 05/04/2006 | US20060094645 Method for defining and treating chemically-induced immune disorders using tumor necrosis factor (TFNalpha), interleukin-1 (lL-1), and interleulin-6R(lL-6R) antagonists |
| 05/04/2006 | US20060094644 Capreomycin derivatives and their use as antibacterials |
| 05/04/2006 | US20060094643 Compositions of hyaluronic acid and methods of use |
| 05/04/2006 | US20060094642 Method of increasing bone toughness and stiffness and reducing fractures |
| 05/04/2006 | US20060094641 Method for providing natural therapeutic agents with high therapeutic index |
| 05/04/2006 | US20060094082 Induces modulation of immune system whereby composition stimulates production of macrophage inflammatory protein-3 alpha from hepatoctyes; use in treating hyperproliferative disease, respiratory disorders, cardiovascular disease, neurological conditions, autoimmune, infectious, gastrointestinal disorders |
| 05/04/2006 | US20060094079 Protein for blocking platelet adhesion |
| 05/04/2006 | US20060094043 Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof |
| 05/04/2006 | US20060094013 Salt-inducible kinases 2 and use thereof |
| 05/04/2006 | US20060093684 Seleniferous composition for producing antioxidase in vivo |
| 05/04/2006 | US20060093670 Sustained-release composition process for producing the same and preparation thereof |
| 05/04/2006 | US20060093660 Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
| 05/04/2006 | US20060093655 Method for making a reinforced absorbable multilayered hemostatic wound dressing |
| 05/04/2006 | US20060093653 Periadventitial delivery device |
| 05/04/2006 | US20060093640 Using ultrafiltration and heparin affinity chromatography to recover bone morphogenic proteins for use in induction of bone formation |
| 05/04/2006 | US20060093625 Light chain that cleaves a neurosecretory protein; an HN domain that translocates the light chain across an endosome membrane and an orphanin polypeptide as a targeting moiety; the HC domain is removed or modified to reduce the targeting of the modified Clostridial toxin to the neuromuscular junction |
| 05/04/2006 | US20060093617 Peptides for inducing a CTL and/or HTL response to hepatitis C virus |
| 05/04/2006 | US20060093615 polypeptide that binds to major histocompatibility complex (MHC) proteins and induces cytotoxic t lymphocytes when bound to MHC antigens; anticancer vaccines |
| 05/04/2006 | US20060093614 Platelet glycoprotein Ib alpha fusion polypeptides and methods of use thereof |
| 05/04/2006 | US20060093613 Soluble T cell receptor |
| 05/04/2006 | US20060093612 Use of heat shock proteins to enhance efficacy of antibody therapeutics |
| 05/04/2006 | US20060093608 Low molecular weight protein tyrosine phosphatase (lmw-ptp) as a diagnostic and therapeutic target |
| 05/04/2006 | US20060093606 Compositions and methods of using angiopoietin-like 4 protein |
| 05/04/2006 | US20060093604 Method of treatment and prophylaxis |
| 05/04/2006 | US20060093603 ErbB4 antagonists |
| 05/04/2006 | US20060093602 Inflammatory mediator antagonists |
| 05/04/2006 | US20060093598 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 05/04/2006 | US20060093597 Methods of treating involuntary facial spasms and facial wrinkles |
| 05/04/2006 | US20060093596 Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish |
| 05/04/2006 | US20060093595 Methods, compositions and kits for treating damage to excitable tissue |
| 05/04/2006 | US20060093594 Treatments for contaminant reduction in lactoferrin preparations and lactoferrin-containing compositions |
| 05/04/2006 | US20060093587 Transplants for myocardial scars |
| 05/04/2006 | US20060093585 Providing mammalian cell contacted with agent and adeno-associated virus (AAV), identifying agent that when contacted with mammalian cell enhances AAV transduction after viral binding to membrane of contacted mammalian cell and before second strand synthesis which yields expressible form of viral genome |
| 05/04/2006 | US20060093584 Intravascular delivery of nucleic acid |
| 05/04/2006 | US20060093579 Human recombinant beta-interferon with improved solubility |
| 05/04/2006 | US20060093578 Method and composition for treating multiple sclerosis |
| 05/04/2006 | US20060093577 Combination anti-viral compositions and methods of use |
| 05/04/2006 | US20060093576 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 05/04/2006 | US20060093575 Oxaliplatin anti-resistance agent |
| 05/04/2006 | US20060093574 Methods for epitope-specific and cytokine/anticytokine combination immunotherapies for modulation of pathogenic immune responses in immune mediated diseases |
| 05/04/2006 | US20060093557 Particulate composition |
| 05/04/2006 | US20060093556 Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin |
| 05/04/2006 | US20060093553 Cd26-based therapies for cancers and immune disease |
| 05/04/2006 | US20060092760 Device for mixing and/or injecting cements |
| 05/04/2006 | DE102004051023A1 Desoxo-Nonadepsipeptide Deoxo-nonadepsipeptides |
| 05/04/2006 | CA2592351A1 Transcriptional inhibitor for human k-ras gene |
| 05/04/2006 | CA2589324A1 Nutritional and/or pharmaceutical preparation for use in prophylaxis and treatment of disturbances in microelements absorption from the alimentary canal |
| 05/04/2006 | CA2586019A1 Kinase inhibitors for the treatment of diabetes and obesity |
| 05/04/2006 | CA2585970A1 Mammalian genes involved in infection |
| 05/04/2006 | CA2585671A1 Use of modulators of epha2 and ephrina1 for the treatment and prevention of infections |
| 05/04/2006 | CA2585638A1 Aminopyridine derivatives having aurora a selective inhibitory action |
| 05/04/2006 | CA2585457A1 Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds |
| 05/04/2006 | CA2585287A1 Melanocortin receptor binding mimetibodies, compositions, methods and uses |
| 05/04/2006 | CA2585268A1 Methods for lowering hif-1 mediated gene expression |
| 05/04/2006 | CA2585265A1 Method to promote wound healing |
| 05/04/2006 | CA2584879A1 Presbyopia treatment by lens alteration |
| 05/04/2006 | CA2584732A1 Vwfa and/or ant_ig domain containing proteins |
| 05/04/2006 | CA2584489A1 Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders |
| 05/04/2006 | CA2584481A1 Pharmaceutical compositions based on nk2 antagonists for pediatric use |
| 05/04/2006 | CA2584331A1 Compositions and methods for modulating pgc-1.beta. to treat lipid-related diseases and disorders |
| 05/04/2006 | CA2583677A1 Tnf-like weak inducer of apoptosis (tweak) receptor binding domain |
| 05/04/2006 | CA2583026A1 Hcv vaccines for chronic hcv patients |
| 05/04/2006 | CA2582552A1 Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer |
| 05/04/2006 | CA2582143A1 Gene therapy for treatment of heart failure |
| 05/03/2006 | EP1652931A2 Recombinant adenoviruses, preparation and uses thereof for the treatment and/or prevention ofs cancers |
| 05/03/2006 | EP1652924A2 Polypeptide, cDNA encoding the same and use thereof |
| 05/03/2006 | EP1652923A1 Gene overexpressed in cancer |
| 05/03/2006 | EP1652917A1 Rna capable of inhibiting expression of klf5 gene |
| 05/03/2006 | EP1652858A1 Peptides for inducing a CTL and/or HTL response to hepatitis C virus |
| 05/03/2006 | EP1652856A1 Stress proteins-derived peptides and method of use thereof |
| 05/03/2006 | EP1652855A1 Polypeptides having brain disposition activity and utilization of the same |
| 05/03/2006 | EP1652539A1 Method of manufacturing a stent comprising an anti-angiogenic composition |
| 05/03/2006 | EP1652534A2 Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer |
| 05/03/2006 | EP1652531A1 Use of GLP-1 or Analogues in Treatment of Stroke |
| 05/03/2006 | EP1652530A1 Drug promoting ceramide transport, base sequence for producing the drug, method of measuring activity of promoting ceramide release and method of measuring activity of promoting intermembrane ceramide transfer |
| 05/03/2006 | EP1652518A1 Pharmaceutical composition for sublingual administration |
| 05/03/2006 | EP1651763A1 Short interfering rna as an antiviral agent for hepatitis c |
| 05/03/2006 | EP1651762A2 Small interfering rna specific to sub-units $g(a), $g(a)' and $g(b) of the kinase protein ck2, and the applications of the same |
| 05/03/2006 | EP1651672A2 Cyclic cadherin analogues comprising the sequence hav for modulating the migration of vascular smooth muscle cells |
| 05/03/2006 | EP1651671A2 Epha2 t-cell epitope agonists and uses therefor |
| 05/03/2006 | EP1651670A2 Novel therapeutic fusion proteins |
| 05/03/2006 | EP1651667A1 Protein with fusogenic activity, nucleic acid sequences encoding said protein and pharmaceutical compositions comprising the same |
| 05/03/2006 | EP1651665A1 Method for the purification of a non-immunoglobulin protein comprising an immunoglobulin-like (ig-like) domain |
| 05/03/2006 | EP1651662A2 Antagonistic analogs of gh-rh (2003) |
| 05/03/2006 | EP1651271A2 Compositions and methods for treating coronavirus infection and sars |
| 05/03/2006 | EP1651267A1 Methods of therapy for chronic lymphocytic leukemia |
| 05/03/2006 | EP1651254A1 Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, in combination with alpha 1-antitrypsin polypeptides, or nucleic acids encoding them, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds |
| 05/03/2006 | EP1651253A1 Connective tissue derived polypeptides |
| 05/03/2006 | EP1651252A2 Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity |
| 05/03/2006 | EP1651251A2 Methods for treating diabetes and related disorders using pde10a inhibitors |
| 05/03/2006 | EP1651250A1 Use of human growth hormone in multiple system atrophy |
| 05/03/2006 | EP1651249A1 Use of calcitonin in osteoarthritis |
| 05/03/2006 | EP1651248A1 Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form |
| 05/03/2006 | EP1651247A1 Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin |
| 05/03/2006 | EP1651246A2 Method for promoting bone growth |
| 05/03/2006 | EP1651216A2 Infection prophylaxis using immune response modifier compounds |
| 05/03/2006 | EP1651190A2 Formulations containing an immune response modifier |